SCHEMBL4199371

SCHEMBL4199371

COc1ccc(NS(=O)(=O)c2cccc3ccccc23)c2c1C[C@@H](N1CCCC1)CC2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.44
HTR7 P34969 1/20 0.43
NPY5R Q15761 6/20 0.42
NPY1R P25929 5/20 0.42
HTR6 P50406 2/20 0.41
QRFPR Q96P65 1/20 0.41
ERAP2 Q6P179 1/20 0.40
ERAP1 Q9NZ08 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
BRD4 O60885 1/20 0.39
CYP17A1 P05093 1/20 0.39
MAPK1 P28482 1/20 0.39
SLC40A1 Q9NP59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4210918 0.86 ALDH1A1 (0.54) GHSRHTR7HTR6ALDH1A1MEN1
SCHEMBL4214204 0.82 HTR6 (0.59) GHSRHTR7NPY5RHTR6QRFPR
SCHEMBL4524885 0.79 HSD11B1 (0.52) HTR6QRFPRERAP2ERAP1ALDH1A1
SCHEMBL4205612 0.78 HTR6 (0.47) HTR7HTR6QRFPRALDH1A1MEN1
SCHEMBL4978402 0.78 HTR6 (0.47) HTR7HTR6QRFPRALDH1A1MEN1
SCHEMBL4210810 0.78 DRD2 (0.42) GHSRHTR7HTR6QRFPRBRD4
SCHEMBL4518573 0.76 HTR6 (0.69) HTR6QRFPRALDH1A1KDM4EMEN1
SCHEMBL4513802 0.74 HTR6 (0.53) HTR7HTR6QRFPRALDH1A1KDM4E
SCHEMBL4520356 0.73 HTR6 (0.52) HTR6QRFPRALDH1A1KDM4EMEN1
SCHEMBL4512103 0.73 HSD11B1 (0.52) HTR6QRFPRERAP2ERAP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D GHSR 283/4885HTR7 7/4885NPY5R 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.